Business Wire

Sonar’s New, Powerful Deep-Analysis Capability Finds Hidden Code Level Security Issues

2.8.2023 16:00:00 EEST | Business Wire | Press release

Share

Sonar, the leading Clean Code solution provider, today announced a significant advancement of its Clean Code offering – developers can now automatically discover and fix code security issues arising from interactions between user source code and third-party, open-source libraries.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230802497889/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Sonar deeper SAST finds hidden code level security issues (Graphic: Business Wire)

Referred to as deeper SAST, the new advanced detection addresses issues that traditional SAST tools miss by not following the flow within library code. Traditional SAST vendors analyze user application code. These tools do not scan the combined code, and flag libraries in an unsophisticated way, ignoring the context and use within the library. The result is that library features are considered black boxes, leaving organizations in the dark about whether they're truly secure for a given context or not. Moreover, these tools typically support only a handful of popular frameworks, often requiring up-front configurations for setup. All of this leads to the security issues created by the unique usage of third-party open source libraries going undetected.

“Code is code, whether it is written by a developer in your team or whether it comes as part of a library that is solving a specific problem. The two different approaches always bothered me, and I am thrilled that we are now able to analyze all codes the same way at once, solving what was considered an impossible problem,” said Olivier Gaudin, CEO and co-founder of Sonar. “With the deeper SAST advancements made to our Clean Code solution, organizations can discover these vulnerabilities and resolve them quickly as code is developed.”

Sonar addresses the gap of traditional SAST through its fine-grained analysis of user source code interactions with external dependencies, all without the need for any special configuration or incremental costs. This deeper SAST innovation furthers Sonar’s mission to equip organizations to achieve a state of Clean Code — code that is consistent, intentional, adaptable, and responsible. When code adheres to these characteristics, software becomes reliable, maintainable, and secure.

“It’s estimated that over 90% of applications leverage third-party libraries and interact with the code within them, but most SAST tools don’t tell developers which dependencies make their code vulnerable. Security is mission-critical, and the more issues you find and fix before they have the ability to cause you harm, the better off your business will be,” said Rik Turner, a Senior Principal Analyst covering cybersecurity at Omdia. “This is the essence of the proactive security wave we are seeing across the cyber sector: find it and fix it before it’s exploited.”

Sonar deeper SAST functionality is available at no additional cost within commercial editions of SonarQube (self-managed) and SonarCloud (cloud-based) — industry-leading static analysis code review tools that continuously inspect and analyze the codebase using quality gates to determine if code meets the defined standards for development and production. Deeper SAST currently supports Java, C#, and TypeScript programming languages and covers thousands of the topmost and commonly used open-source libraries, including their subsequent (transitive) dependencies.

Achieving a Clean Code State

Sonar empowers development teams to write Clean Code by providing them with the right tools and best practices, so they can spend less time fixing issues and more time meeting delivery and business goals. Pairing the Sonar solution with the company’s Clean as You Code methodology — set standards for keeping new, added, or edited code clean — and its educational guidance for code called ‘Learn as You Code,’ developers have faster issue remediation and delivery, code enhancement, and can further professional growth and team retention. Today, there are over seven million developers using Sonar.

Sonar also actively engages with its ecosystem and customer communities, in addition to partnerships with several universities for security research projects, and the open source software and start-up communities. Additionally, Sonar has a dedicated team of security researchers that find and responsibly disclose exploitable zero-day vulnerabilities in open-source software; these findings are used as inspiration for new security rules and detections to help find vulnerabilities.

Learn more about our deeper SAST innovation and Sonar solution (SonarQube, SonarCloud, SonarLint). Meet Sonar experts at Black Hat USA, booth #2760, August 8-10.

About Sonar

Sonar empowers developers and organizations to systematically achieve a state of Clean Code so that all code is fit for development and production. By applying the Sonar Clean as You Code methodology, organizations minimize risk, reduce technical debt, and derive more value from their software in a predictable and sustainable way.

The open source and commercial Sonar solution – SonarLint, SonarCloud, and SonarQube – supports over 30 programming languages, frameworks, and infrastructure technologies. Trusted by more than 400,000 organizations globally to clean more than half a trillion lines of code, Sonar is integral to delivering better software.

To learn more about Sonar, please visit https://www.sonarsource.com/company/about/.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Katie Hyman
Senior PR Manager, Sonar
katie.hyman@sonarsource.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye